JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01877 JUNSHI BIO

Not Yet Opened 12-31 12:08:29

21.340

-0.240

-1.11%

High21.720	Low21.080	Vol2.26M
Open21.620	D1 Closing21.580	Amplitude2.97%
Mkt Cap21.92B	Tradable Cap5.55B	Total Shares1.03B
T/O48.15M	T/O Rate0.87%	Tradable Shares260.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":21.34,"timestamp":1767154109004,"preClose":21.58,"halted":0,"volume":2264400,"delay":0,"floatShares":260000000,"shares":1027000000,"eps":-1.4508800211828108,"marketStatus":"Not Yet Opened","change":-0.24,"latestTime":"12-31 12:08:29","open":21.62,"high":21.72,"low":21.08,"amount":48153606,"amplitude":0.029657,"askPrice":21.34,"askSize":45000,"bidPrice":21.3,"bidSize":5600,"shortable":3,"etf":0,"ttmEps":-1.070256156425712,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767317400000},"marketStatusCode":0,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":21.58,"openAndCloseTimeList":[[1767144600000,1767153600000]],"volumeRatio":1.8279446422541854,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co.,Ltd.","latestPrice":34.16,"timestamp":1767164400000,"preClose":34.33,"halted":0,"volume":5343800,"delay":0,"premium":"-44.03"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2591697940","title":"Shanghai Junshi Biosciences Gets US FDA Approval for Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697940","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591697940?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:35","pubTimestamp":1765776943,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  obtained the approval of the U.S. Food and Drug Administration for the clinical trial application for JS212 to treat advanced solid tumors.JS212 is designed to target both epidermal growth factor receptor and human epidermal growth factor receptor 3, which are commonly overexpressed in lung and colorectal cancers, according to a Monday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK0239","01877","BK1583","688180","BK1515"],"gpt_icon":0},{"id":"1186550543","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 4% as FDA Approves JS212 Clinical Trial for Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1186550543","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186550543?lang=en_us&edition=fundamental","pubTime":"2025-12-15 09:50","pubTimestamp":1765763413,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged more than 4%, reaching HK$25 by the time of writing, with a trading volume of HK$34.83 million. The rise follows the company's announcement on December 14 that the U.S. Food...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK0239","BK1161","688180","BK1583","BK1515"],"gpt_icon":0},{"id":"2590533142","title":"BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2590533142","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590533142?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:41","pubTimestamp":1765377687,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLNDec 10  - Shanghai Junshi Biosciences Co Ltd 688180.SS:CHAIRMAN XIONG JUN INTENDED TO INCREASE SHAREHOLDING IN A SHARES AND H SHARES FOR NO LESS THAN RMB100 MILLIONFurther company coverage: 688180.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01877","BK1515","688180","BK0239"],"gpt_icon":0},{"id":"2590819125","title":"Shanghai Junshi Biosciences -  Chairman Xiong Jun Intended to Increase Shareholding in a Shares and H Shares for No Less Than RMB100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2590819125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590819125?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:58","pubTimestamp":1765367887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK0239","688180","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2589038430","title":"Junshi Biosciences' Application for Plaque Psoriasis Drug Gets China Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589038430","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589038430?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:28","pubTimestamp":1765175328,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  new drug application for the roconkibart injection was accepted by China's National Medical Products Administration, a Dec. 5 Hong Kong bourse filing said.Shares of the healthcare company were up 1% in Monday afternoon trading.The drug is for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","01877","BK1161","BK1583","688180","BK1515"],"gpt_icon":0},{"id":"2589384823","title":"Junshi Biosciences' Four Drugs Placed on China's Insurance Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384823","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589384823?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:23","pubTimestamp":1765174985,"startTime":"0","endTime":"0","summary":"Four drugs under Shanghai Junshi Biosciences  were included in China's  National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance list, according to a Sunday disclosure on the Hong Kong bourse.The pharmaceutical company's Shanghai and Hong Kong shares both rose less than 1% during Monday's afternoon trade.The drugs included on the list are toripalimab injection or Tuoyi, adalimumab injection or Junmaikang, deuremidevir hydrobromide tablets or Mindewei, and ongericimab injection or Junshida.Tuoyi is the only anti-PD-1 monoclonal antibody on the list for the treatment of renal cancer, triple-negative breast cancer and melanoma.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","688180","BK0239","BK1161","BK1583","01877"],"gpt_icon":0},{"id":"1185043125","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1185043125","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185043125?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:38","pubTimestamp":1765157897,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK1583","BK0239","01877","BK1515","BK1161"],"gpt_icon":0},{"id":"2589880131","title":"Shanghai Junshi Biosciences (SEHK:1877): Reassessing Valuation After a Sharp Pullback and Strong Year-to-Date Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2589880131","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589880131?lang=en_us&edition=fundamental","pubTime":"2025-12-08 03:10","pubTimestamp":1765134622,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences (SEHK:1877) has quietly pulled back after a strong year to date, and that dip is starting to catch investors’ attention as they reassess the biotech’s growth profile and risks.\nSee our latest analysis for Shanghai Junshi Biosciences.\nDespite the recent pullback, Shanghai Junshi Biosciences is still sitting on a strong year to date share price return. This suggests that earlier optimism about its drug pipeline and earnings trajectory is now cooling as investors...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-reassessing-valuation-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-reassessing-valuation-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","01877","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2589137278","title":"BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2589137278","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589137278?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:51","pubTimestamp":1764946319,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug ApplicationDec 5 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:ACCEPTANCE OF NEW DRUG APPLICATION FOR ROCONKIBART INJECTION BY NMPAFurther company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1515","688180","01877","BK0239","BK1161"],"gpt_icon":0},{"id":"2589892346","title":"Shanghai Junshi Biosciences - Acceptance of New Drug Application for Roconkibart Injection by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892346?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:33","pubTimestamp":1764938006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","01877","BK1583","BK1515","BK1161","688180"],"gpt_icon":0},{"id":"1145157960","title":"Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1145157960","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145157960?lang=en_us&edition=fundamental","pubTime":"2025-12-05 17:34","pubTimestamp":1764927260,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The new drug application...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01877","BK0239","BK1515","688180"],"gpt_icon":0},{"id":"1198166631","title":"Junshi Bio (HKEX: 1877, SSE: 688180) Announces Share Reduction Results of Major Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=1198166631","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198166631?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:45","pubTimestamp":1764848749,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. disclosed that Shanghai Tanying Investment Partnership (LP), previously holding 71,459,326 A shares (6.9602% of total share capital), completed a shareholding...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"gpt_icon":0},{"id":"1138520658","title":"Shanghai Junshi Biosciences (01877, 688180) Announces November 2025 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1138520658","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138520658?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:44","pubTimestamp":1764837872,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. released its monthly return for the period ended 30 November 2025. The total registered capital remained RMB 1,026,689,871, which includes 260,295,700 H shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0082770016.SGD","LU0329678170.USD","02567","LU1166156734.SGD","LU1675838814.USD","LU2153592121.USD","BK1184","BK1618","BK1502","00302","LU0051755006.USD","LU0823397103.USD","LU1951186391.HKD","LU0164880469.USD","02273","BK1128","BK1583","BK1615","BK1132","00867","LU0164865239.USD","00451","BK1233","LU0509642566.USD","LU2488822045.USD","03680","LU1634259557.SGD","LU1366334578.USD","BK1587","BK1613","BK1530","LU0823426480.USD","00384","LU0431992006.USD","LU1152091168.USD","02858","02488","BK1137","BK1179","01640","LU0314109678.HKD","SG9999004311.SGD","LU0140636845.USD","BK1190","BK1616","LU2357125470.USD","LU1969619763.USD","01911","BK1610","LU0634319403.HKD","LU1720050803.USD","LU0588545490.SGD","BK1606","LU1366334651.USD","BK1114","SG9999001226.SGD","00798","BK1140","02587","LU0650527681.SGD","LU1303224171.USD","BK1197","BK1104","IE00BVYPNQ40.USD","02451","BK1209","IE00BQXX3D17.EUR","LU0541502299.USD","LU0572939691.SGD","LU1102505929.USD","IE0009570106.USD","LU0823039010.USD","03709","BK1607","LU0348735423.USD","09860","IE00B0169L03.USD","02886","03145","LU0488056044.USD","BK1523","SG9999000418.SGD","IE00BZ08YS42.EUR","BK1222","LU0261950470.USD","01783","LU1981816686.USD","LU2506951792.HKD","02250","BK1578","LU0269904917.USD","LU0516422440.USD","BK1230","BK1560","LU0819121731.USD","00135","SG9999014674.SGD","LU0229945570.USD","BK1095","01530","02400","SG9999006514.SGD","LU0348784397.USD","BK1552","06060","BK1553","LU1993786604.SGD","09880","09919","BK1548","02392","LU0254981946.USD","01333","02436","LU2039709279.SGD","LU1226288170.HKD","BK1509","BK1186","BK1544","LU0052750758.USD","LU0823414478.USD","LU0359202008.SGD","LU0048597586.USD","01969","BK1521","BK1164","BK1258","02279","BK1556","BK1228","BK1257","LU0620787316.HKD","LU1939255532.USD","LU0261947096.USD","01458","02155","01448","02298","LU0149721374.USD","BK1582","BK1170","LU0823414551.USD","HK0000320264.USD","LU2097828714.EUR","03896","00382","BK1571","LU0359201612.USD","00826","BK1183","02420","06996","BK1555","01877","00992","BK1227","09690","03800","06919","BK1169","LU0880133367.SGD","LU0348805143.USD","02167","00777","02590","BK1124","LU0348767384.USD","LU0345775950.USD","LU0348825331.USD","IE0003851619.USD","BK1219","01519","LU0211977185.USD","BK1540","LU0052756011.USD","09699","LU0708995583.HKD","LU0455707207.USD","01117","BK1220","02020","LU0072462343.USD","82331","09990","BK1519","IE00BGV7N243.SGD","BK1171","LU0320764599.SGD","LU1868837722.USD","LU0463099449.HKD","LU0593848301.USD","02627","IE00B5MMRT66.SGD","LU0737861772.HKD","01378","09955","LU1328277881.USD","LU0310800965.SGD","IE00BMCWC346.EUR","02121","LU2106854487.HKD","09877","02525","02511","BK1564","00460","02419","HK0000500386.USD","LU0449515922.USD","02018","BK1541","02158","LU0823426308.USD","BK1595","IE00BGHQDM52.EUR","ANPDY","LU0871576103.HKD","09660","BK1531","SG9999001903.USD","LU0865486749.SGD","LU1508157978.USD","HK0000320223.HKD","IE0008368742.USD","BK1117","01585","BK1590","09923","02331","01070","BK1619","02190","SG9999001069.SGD","01211","LU0164872284.USD","LU0327786744.USD","09678","00855","BK1239","02411","BK1500","01833","02460","BK1214","BK1586","LU0259732245.USD","IE00BZ08YT58.USD","LU0868486357.SGD","BK1247","BK1588","BK1604","LU0011963245.USD","IE00BD6J9T35.USD","06168","01177","LU0054237671.USD","BK1200","02157","02197","SG9999000459.SGD","02431","LU0856984785.SGD","LU1226288253.USD","BK1144","01762","00861","SG9999002950.SGD","BK1151","LU0516422366.SGD","BK1142","BK1189","LU2125910500.SGD","BK1608","LU0823038988.USD","02256","LU1188198961.HKD","LU2506952253.HKD","BK1542","BK1136","01384","LU0417516571.SGD","LU0540923850.HKD","LU0543330566.HKD","LU2023250504.SGD","06069","01405","LU0516422952.EUR","00512","BK1240","BK1253","BK1504","02453","06633","02696","LU2242644610.SGD","03650","LU0456827905.SGD","LU0214875030.USD","LU0244354667.USD","02498","02509","LU0082770016.USD","LU0289739343.SGD","LU1522347837.USD","SG9999004220.SGD","02013","09961","BK1524","LU2097828805.USD","LU0173614495.USD","BK1110","BK1557","02057","BK1237","LU1831875114.USD","06683","02552","06821","00363","BK1119","LU0762540952.USD","LU0979878070.USD","03939","LU0469268626.HKD","LU0165289439.USD","IE00BZ08YR35.GBP","00999","BK1134","02533","LU1267930227.SGD","BK1178","02556","02650","06963","IE00B543WZ88.USD","LU1634259391.SGD","03677","01939","LU1808992512.USD","02096","SG9999000475.SGD","SG9999015978.USD","06862","LU0499858602.USD","LU1282649067.USD","LU0499858438.USD","BK1225","LU0417516738.SGD","HK0000165453.HKD","BK1589","LU0348766576.USD","02177","BK1168","01773","01093","LU0261950983.USD","00699","LU0307460666.USD","BK1207","09878","LU0251143458.SGD","LU0541501648.USD","02506","002594","02105","BK1131","LU0348783233.USD","LU0588546209.SGD","02100","BK1111","BK1109","BK1154","BK1215","SGXZ62798434.SGD","LU1115378108.SGD","LU1770034418.SGD","06058","LU1102505762.USD","06160","LU2097828631.EUR","IE00BQXX3C00.GBP","LU0359201885.HKD","LU0594300419.USD","02670","BK1116","06913","LU0264606111.USD","00656","LU2778985437.USD","IE00BVYPNP33.GBP","IE00B031J352.USD","LU0417516902.SGD","BK1212","BK1221","LU1211504680.USD","01952","LU1497733557.USD","BK1216","LU0501845795.SGD","LU2663582299.SGD","BK1163","80992","SGXZ90724238.SGD","IE00B29SXG58.USD","LU1152091754.HKD","BK1191","LU2177674079.SGD","BK1597","LU0289960550.SGD","IE0032431581.USD","LU2153591404.USD","LU0054450605.USD","LU0588545730.USD","02551","IE00B8HQ1Z84.USD","LU0315179316.USD","LU2249611893.SGD","00884","BK1539","03396","LU1961090484.USD","02629","IE0003795394.USD","BK1526","BK1549","LU0128525689.USD","LU1770036033.HKD","06988","LU1807302812.USD","02145","09985","BK1609","IE0008369823.USD","LU1242518857.USD","BK1559","02889","BK1139","01440","IE0034224299.USD","BK1600","LU0531971595.HKD","LU0084288322.USD","03681","LU2476274720.SGD","06677","80020","LU2360107325.USD","LU1861219969.SGD","LU1226287529.USD","00020","SG9999001093.SGD","BK1596","06618","BK1512","SG9999015986.USD","09639","09911","02142","06609","81211","LU0702159699.USD","LU1813983027.USD","HK0000306701.USD","LU0039217434.USD","BK1235","06855","SG9999011746.SGD","00305","01600","LU2238339852.HKD","BK1100","LU0043850808.USD","LU0561508036.HKD","LU2097828557.USD","LU1974910355.USD","LU2424517915.HKD","HK0000306685.HKD","LU1880383366.USD","BK1150","LU2298064838.USD","LU0384037296.USD","01471","BK1522","BK1527","BK1577","LNNGY","LU0287142896.SGD","LU0449509016.USD","LU1039395188.USD","00666","01318","BK1575","LU0531970944.HKD","LU0791591158.USD","01907","LU0791590937.USD","SGXZ86797644.SGD","09956","HK0000252152.HKD","HK0000252160.HKD","LU0605514214.HKD","LU2008162690.USD","BK1528","LU0737861699.HKD","01164","LU1224709979.USD","LU1868837565.USD","BK1096","BK1585","06086","BK1194","LU0048580855.USD","LU2097828474.EUR","01651","02616","01681","BK1167","SG9999002562.SGD","BK1598","LU1917777945.USD","LU0049112450.USD","00267","LU0572940350.SGD","LU0511384066.AUD","BK1224","LU1719994722.HKD","LU2328871848.SGD","LU2399975544.HKD","IE00BYV24P56.USD","LU0348827113.USD","LU0640798160.USD","HYDD.SI","SG9999001051.SGD","LU0823437842.USD","02150","01739","LU0164939612.USD","LU0611395673.USD","LU0107464264.USD","02228","BK1126","LU1497734951.SGD","LU0828238088.HKD","BK1193","09996","02276","BK1593","01119","LU0505663152.USD","86618","BK1147","LU1242518931.SGD","01880","LU0274383008.USD","LU0370786039.SGD","LU0819123356.HKD","LU0143863198.USD","BK1520","LU0831093199.SGD","BK1158","LU1880383440.USD","BK1516","IE00B0JY6N72.USD","06608","BK1195","BK1155","BYDDY","BK1592","IE00BPRC5H50.USD","LU1008478684.HKD","LU1328615791.USD","LU0572944931.SGD","01276","LU1861214812.USD","LU1497733631.SGD","LU0143863784.USD","LU0329678337.USD","LU1794554557.SGD","LU0516423091.SGD","09636","03836","LU1048588211.SGD","01818","LU2476274308.USD","LU1868838027.USD","BK1229","IE00B031HY20.USD","BK1160","LU0231483743.USD","LU3063872942.SGD","02171","BK1141","00300","02268","BK1148","LU0289961442.SGD","BK1175","BK1161","06186","09992","BK1143","BK1566","BK1550","00875","LU1481107354.HKD","02565","BK1518","82020","06657","06613","LU1226287792.SGD","01809","03658","09926","BK1591","01520","LU0828237510.HKD","LU0588545904.SGD","IE00BQXX3F31.USD","BK1127","06138","LU0048575426.USD","LU1046422090.SGD","IE0031814852.USD","SG9999002828.SGD","LU0067412154.USD","LU0594300179.USD","LU2348773727.SGD","00960","LU0516423174.USD","09927","02315","02469","02380","02382","LU0502904849.HKD","LU2348774022.SGD","SG9999002463.SGD","02598","BK1515","LU0315178854.USD","BK1579","LU2294711713.HKD","BK1125","06090","LU1023057109.AUD","LU0456846285.SGD","LU1226287875.USD","LU2543165471.USD","LU0345776255.USD","LU2449936058.SGD","09890","LU0823397285.USD","BK1574","LU0251144936.SGD","SG9999006597.SGD","BK1617","LU1956131251.USD","SG9999015945.SGD","BK1198","BK1605","IE00B8L5B284.USD","06100","SG9999003461.SGD","00017","09959","LU2045819591.USD","LNVGY","01735","BK1554","LU0175139822.USD","02595","LU2460026573.USD","03738","BK1594","LU0326950275.SGD","LU0228659784.USD","LU1282649810.SGD","00003","BK1188","LU1235295612.USD","LU1960683339.HKD","LU0072913022.USD","LU1251922891.USD","00136","03998","SG9999015952.SGD"],"gpt_icon":1},{"id":"1155375642","title":"JUNSHI BIO (01877) Plans to Utilize Idle Raised Funds for Cash Management","url":"https://stock-news.laohu8.com/highlight/detail?id=1155375642","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155375642?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:34","pubTimestamp":1764243250,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) announced that the company will strictly control risks in accordance with relevant regulations and intends to invest temporarily idle raised funds in safe, highly liquid...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","688180","BK1583","BK1515","BK1161","BK0239"],"gpt_icon":0},{"id":"1162501983","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 5% Again as Toripalimab Subcutaneous Injection Phase III Trial Meets Primary Endpoint, Plans Submission for Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1162501983","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162501983?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:12","pubTimestamp":1764126733,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged more than 5% again, with shares up 4.43% to HK$25.48 at the time of writing, recording a turnover of HK$46.15 million. The company announced that its self-developed...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","III","BK1515","BK1161","688180","01877","BK4134","BK1583"],"gpt_icon":0},{"id":"2586449658","title":"BUZZ-Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2586449658","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586449658?lang=en_us&edition=fundamental","pubTime":"2025-11-25 13:44","pubTimestamp":1764049490,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment ** Hong Kong-listed shares of Shanghai Junshi Biosciences 1877.HK rise 5.9% to HK$25.2, their biggest intraday pct gain since October 31** Stock touches its highest level since November 18, and set for a second session of gains** Shanghai-listed shares 688180.SS climb 3.5% to 37.52 yuan, their highest point since November 19** The China-based innovative drug developer plans to submit new drug application of its product toripalimab injection  to regulatory authorities in the near future ** JS001sc is a subcutaneous injection for treatment of recurrent or metastatic non-squamous non-small cell lung cancer** Phase III clinical study of JS001sc for the first-line treatment of non-squamous non-small cell lung cancer has met the primary endpoints, says Shanghai Junshi ** YTD, Hong Kong stock up 114.9%, Shanghai-listed shares up 36.9%, Hang Seng Biotech Index .HSBIO up 81.5%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL1N3X103D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","01877","688180","BK1161","BK1583","BK1515"],"gpt_icon":0},{"id":"2586445692","title":"Shanghai Junshi Says JS001 Subcutaneous Injection Meets Goal of Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2586445692","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586445692?lang=en_us&edition=fundamental","pubTime":"2025-11-25 12:14","pubTimestamp":1764044067,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  said a subcutaneous injection version of its JS001 cancer medicine worked as well as the regular injection version as a first-line treatment of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.Shares of the healthcare company gained over 5% in morning trade Tuesday.Results from a late-stage study showed that JS001sc was non-inferior to JS001, or toripalimab, with comparable efficacy and safety profiles in treating recurrent ormetastatic non-squamous non-small cell lung cancer, meeting the main goal of a late-stage study called JS001sc-002-III-NSCLC.The firm said it planned to submit a new drug application for the subcutaneous injection version of the drug with regulatory authorities in the near future.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1515","BK1161","SSI","01877"],"gpt_icon":0},{"id":"1101285616","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Nearly 5% as JS001sc Meets Primary Endpoint in Phase III Lung Cancer Trial; Company to Submit Marketing Authorization Application Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1101285616","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101285616?lang=en_us&edition=fundamental","pubTime":"2025-11-25 10:26","pubTimestamp":1764037573,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) rose nearly 5% in trading, reaching HK$24.92 with a turnover of HK$32.54 million. The company announced that its self-developed toripalimab injection (subcutaneous) (product code:...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","688180","01877","BK4134","BK1161","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"1168233496","title":"Shanghai Junshi Biosciences (1877) Announces Positive Phase III Results for JS001sc in Non-Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1168233496","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168233496?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:03","pubTimestamp":1763989421,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (1877) announced that a multi-center, open-label, randomized controlled phase III clinical study (NCT06505837) comparing JS001sc (toripalimab injection,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.0541},{"period":"1month","weight":-0.1388},{"period":"3month","weight":-0.3458},{"period":"6month","weight":-0.1378},{"period":"1year","weight":0.8428},{"period":"ytd","weight":0.8428}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.2777},{"period":"ytd","weight":0.2777}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.112475},{"month":2,"riseRate":0.857143,"avgChangeRate":0.07747},{"month":3,"riseRate":0.714286,"avgChangeRate":0.049127},{"month":4,"riseRate":0.857143,"avgChangeRate":0.101581},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"JUNSHI BIO","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"JUNSHI BIO,01877,JUNSHI BIO股票,JUNSHI BIO股票老虎,JUNSHI BIO股票老虎国际,JUNSHI BIO行情,JUNSHI BIO股票行情,JUNSHI BIO股价,JUNSHI BIO股市,JUNSHI BIO股票价格,JUNSHI BIO股票交易,JUNSHI BIO股票购买,JUNSHI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}